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Abstract
Methods for site-specific modification of proteins are in high demand. Reactions that yield
bioconjugates should be quantitative, site-specific, and versatile with respect to nature and size of
the biological/chemical targets involved, require minimal modification of the target, display
acceptable kinetics under physiological conditions, and be orthogonal to other labeling methods.
Sortase-mediated transpeptidation reactions meet these criteria. Here we describe the expression
and purification conditions for two orthogonal sortase A enzymes and provide the protocol that
allows functionalization of any given protein at its C-terminus or for select proteins at an internal
site. Sortase-mediated reactions take only a few minutes, but reaction times can be extended to
increase yields.
INTRODUCTION
One of the goals of protein engineering is the installation of desirable features, template-
encoded or otherwise, on proteins that naturally lack them. The ability to confer different
functionalities onto a protein of interest enables a broad array of applications. Attachment of
a fluorophore to a protein allows its use in live-cell microscopy, while generation of a fusion
between an antibody and a payload of interest, such as a toxin or an antigen, can find use in
therapeutics and vaccine development, respectively.
Several strategies based on genetic, chemical, enzymatic, or chemo-enzymatic methods
equip proteins with functional groups. Genetic engineering is the method of choice when
modification at a precise site is required. However, the effect of the genetically appended
sequence on expression, folding, and function of the final product is difficult to predict.
Some proteins are simply refractory to the construction of functional fusions by standard
genetic means 1. The range of modifications that can be applied to a protein as a fusion
product is limited in the first instance to those that are template-encoded. Chemical
modifications of proteins are more versatile but lack precision, as they usually target
exposed cysteine or lysine residues. Moreover, because the reactions often call for non-
physiological reaction conditions (pH, reducing conditions, ionic composition), chemical
damage of the target protein can occur. While enzymatic methods can overcome some of
drawbacks and afford site-specific protein modification, they often require genetic
installation of sizable catalytically active protein domains (such as the O6-alkylguanine-
DNA alkyltransferases (SNAP or CLIP-base technology 2,3), haloalkane dehalogenases
(halo-tag technology, 20–40 kDa, 4) onto the protein substrate; installation of the 15-amino
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acid BirA acceptor peptide 5, the use of which is limited to biotin and its synthetically
demanding chemical derivatives; engineering of a 13-amino acid acceptor peptide for lipoic
acid ligase 6, with the limitation that it primarily accepts lipid substrates and therefore
mutant screens are required to incorporate new functionalities; the use of the formylglycine-
generating enzyme that converts a cysteine residue within the context of a LCTPSR
sequence (aldehyde tag) into formylglycine that can be used in oxime ligations 7,8; or
exploiting the enzyme phosphopantetheinyl transferase to conjugate CoA-derived molecules
to a specific 11-amino acid sequence 9. Sortase-mediated transpeptidation reactions are a
versatile complement to these protein modification strategies 10,11,12,13 and predominantly
rely on the use of modified peptides, readily accessible by solid phase peptide synthesis
using commercially available building blocks. Using sortases, we achieve labeling with
similar precision afforded by genetic fusions, and moreover provide ready access to protein
derivatives structures that are unattainable genetically.
Sortases and mechanism of action
Gram-positive bacteria display proteins at their surface to enable them to acquire nutrients,
evade host immunity, or adhere to sites of infection 14. Sortases comprise a family of
membrane-associated transpeptidases that anchor those proteins to the cell wall 11,15. The
different members of the sortase family can be divided into four subfamilies, based on their
distinct primary sequence and substrates 16. While sortases A accept a large number of
protein substrates, the sortases of B-D type have more specialized functions and therefore
fewer substrates. In Staphylococcus aureus, proteins targeted to the bacterial surface display
a conserved sortase recognition motif: Leu-Pro-Xxx-Thr-Gly (LPXTG, where X is any
amino acid and Gly cannot be a free carboxylate), at or near their C-terminus. Upon
recognition, sortase A cleaves between the threonine and glycine residues to form an acyl-
enzyme intermediate. The active site cysteine of sortase A bonds with the carbonyl of the
threonine residue of the target protein. This intermediate is then resolved by nucleophilic
attack by the free amino group of the cell wall precursor lipid II. This lipid II-linked protein
conjugate is incorporated during cell wall synthesis and consequently the protein is
displayed at the surface 17 (Fig. 1).
Diversity of applications
Sortase-mediated reactions are applicable to any protein of interest, provided it comprises a
LPXTG motif as the sortase target, or a suitably exposed Gly residue to serve as the
incoming nucleophile. Both modifications (LPXTG, Gly) can be introduced using standard
molecular cloning protocols. Also, sortases A are easily expressed in soluble recombinant
form and in excellent yield in E.coli (see “Expression and production of sortases ”). The
natural nucleophile, lipid II, can be replaced by any peptide with an oligoglycine (Gly1-5) at
the N-terminus. In turn, the peptides can be decorated with any molecule accessible through
chemical synthesis (e.g., fluorophores, biotin, cross-linkers, lipids, carbohydrates, nucleic
acids) 1,10,18,19,20,21,22,23 provided a free N-terminal Gly remains available on the peptide
used as incoming nucleophile. Thus, incubation of sortase, LPXTG-containing protein, and
nucleophile leads to the covalent attachment of that nucleophile to the protein of interest, in
a site-specific manner. Because the oligoglycine peptide that serves as the nucleophile is
functionalized beforehand, the chemical reaction conditions used to incorporate the
functional group inflict damage on neither sortase nor the protein substrate, as long as the
modified oligoglycine peptide remains in solution once added to the sortase reaction.
Proteins can also serve as nucleophiles, provided they display a suitably exposed (stretch of)
glycine(s) at their N-terminus (Gly1-5). Such modification allows the proteins to be N-
terminally labeled with functionalized peptides 24,25 or to form protein-protein
adducts 1,26,27.
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Relying on a common mechanistic principle, sortagging affords ready access to a wealth of
site-specific modifications: C-terminal 10,19,20, internal loop regions 1,28, N-terminal 24,25,
and formation of cyclized (poly)peptides 29,30,31. We have mainly used sortases A derived
from Staphylococcus aureus and Streptococcus pyogenes. Versions of Staphylococcus
aureus with improved Kcat values 32, as well as mutant versions that do not require Ca++
ions 33 have been reported and further extend the range of reaction conditions and
applications. Streptococcus pyogenes sortase A accepts dialanine (poly)peptides as
nucleophiles 34. The possibility of using two orthogonal sortases increases the versatility of
these labeling reactions, as one can attach two different labels to one and the same molecule
of choice 24.
Limitations
More than 50 different substrates including peptides 21,30, soluble proteins 10,20,28,29,
membrane proteins displayed at the cell surface 10,35, M13 bacteriophage 36, budding
influenza virus 37, antibodies 22,26,27, bacterial toxins 1,24, pre-assembled complexes 1,24
have yielded to sortase labeling. We have yet to encounter a protein that could not be labeled
using sortase. One initial limitation of using sortase A from S. aureus was its obligate Ca2+
dependent activity 10. The presence of calcium in the reaction buffer precludes the use of
phosphate-based buffers. Sortase A from S. pyogenes 34 or a mutant form of S. aureus
(E105K/E108A33) are Ca2+ independent and thus circumvent this limitation.
Not every lab is equipped to perform peptide synthesis, and commercial vendors provide
such services. To assist those interested in synthesizing their own peptides, we have
included protocols that describe the synthesis of probes of general utility (biotin and
fluorophores). It requires minimum specialized equipment (reaction vessels for peptide
synthesis) and involves reactions readily executed in a laboratory outfitted for biochemical
work (fume hoods, appropriate organic waste disposal, lyophilizer).
Advantages of the method
• Site-specific.
• Quantitative.
• Versatile with respect to the moieties to be attached to the protein of interest
(biotin, fluorophores, reporter peptides, sugars, lipids, etc).
• Versatile regarding the labeling position on a protein: N-, C-, both N- and C-
terminus, solvent-accessible loops.
• Enable cyclization of proteins or peptides, if N- and C-termini are in close
proximity.
• Carried out under physiological conditions.
• Require minimal modification of the target: 5 amino acid recognition sequence.
• Orthogonal sortases are available.
• Reaction can be performed using sortase A in solution or sortase A immobilized on
a solid-phase support (described elsewhere in this issue of Nature Protocols [ref]).
Experimental design
The components of any sortagging reaction are: sortase, substrate, and nucleophile. Thus,
we have divided this protocol in five sections: “Engineering substrates for sortagging”,
“Expression and production of sortases”, “Peptide synthesis”, and “C-terminal sortagging
reactions ”.
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ENGINEERING SUBSTRATES FOR SORTAGGING
A) C-terminal labeling—Substrates equipped with the LPXTG recognition motif for S.
aureus, or LPXTA for S. pyogenes can be engineered using standard molecular cloning
protocols. Although any amino acid can precede the Thr residue, a glutamic acid is often
used because it is commonly found in the natural sortase A substrates 38. The sortase
recognition sequence is normally engineered at the C-terminus of the protein to be modified,
with the G or A residue in amide linkage, followed by an affinity purification handle (e.g.,
His6) that is lost upon reaction (Fig. 2). The efficiency of the sortase-mediated reaction
depends on the flexibility and accessibility of the region comprising the sortase A-
recognition motif. Thus, if the C-terminus of the protein is known to be hidden (in the
absence of a known structure, a failure to yield to sortase labeling would be a clear
indication of lack of accessibility), we recommend engineering a flexible linker composed of
(Gly4Ser)n preceding the LPETG/A sequence. The length of such linkers needs to be tested
empirically for each protein of interest. Critical step. Identify the first amino acid of the
protein substrate. Gly or Ala residues may cause cyclization as a competing side-reaction
during labeling 29.
(B) Internal loop structure labeling—Site-specific modification of an internal solvent-
exposed region in the protein of interest is a particular case of C-terminal labeling. As long
as the LPXTG/A motif is introduced in an unstructured segment of the substrate protein,
sortase can recognize it 28. An LPXTG motif that is highly structured is usually a poor
sortase substrate 10,28. Flexibility can be ensured through installation of a specific protease
cleavage site, immediately downstream of the sortase motif 1. Upon cleavage, the newly
exposed C-terminus including the LPETG/A motif is likely to be unstructured. Accessibility
to protease cleavage is a useful indicator for successful execution of a subsequent sortase
reaction. Depending on the sequence of the protein, we rely on established site-directed
mutagenesis strategies to engineer or to insert a LPXTG/A motif at the intended site. Since
sortase cleaves the protein at the site of recognition, it is likely that the two halves of the
protein will separate upon sortagging unless otherwise stabilized, for example through a
disulfide bond 1 or for topological reasons 28. Thus, selecting an internal location for a
sortase site in a loop region constrained by a disulfide bond might minimize the risk of such
disintegration (Fig. 3). Critical step. Identifying the adequate protease to use has to be
tested empirically to ensure that the protease does not cleave elsewhere within the protein.
Trypsin and Factor Xa are examples of proteases used for this purpose 1.
EXPRESSION AND PRODUCTION OF SORTASES
We commonly use three different sortases: the Ca2+ dependent sortase A from S. aureus, its
mutant version [E105K/E108A 33] and sortase A from S. pyogenes; the latter two are Ca2+
independent. Because sortase is a membrane protein in Gram-positive bacteria, we use
versions where the transmembrane domain has been eliminated and replaced with a
hexahistidine purification tag. Two soluble versions exist for S. aureus wild-type sortase A,
with either a N-terminal deletion of 25 amino acids 17 or 59 amino acids. The enzymatic
activity of both versions is identical 39, but the molecular weight is different. This is a useful
trait to explore in those cases where the molecular weights of the protein to be labeled and of
the sortase to be used are similar. In addition, we equipped the Δ59 truncated version with a
thrombin cleavage site that releases the His tag upon digestion. This not only facilitates
further downstream purification but also increases the mobility of sortase in SDS-PAGE
gels, allowing a clear-cut distinction between sortase and substrate if so required.
The following standard procedure for protein expression and purification yields
approximately 40 mg L−1 S. aureus sortase A and 10 mg L−1 S. pyogenes sortase A.
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MATERIALS
REAGENTS
• pQE30 sortase A S. aureus (Δ25), available upon request 17
• pET28a sortase A S. aureus (Δ59), available upon request
• pET28a sortase A S. aureus (Δ59, E105K, E108A, Ca2+ independent), available
upon request
• pET28a sortase A S. pyogenes (Δ81), available upon request
• E. coli BL21(DE3) (Invitrogen C6000-03)
• Kanamycin (Fisher Scientific, cat. no. BP906-5)
• Ampicillin (Sigma, cat. no. A0166)
• Luria-Broth (LB) medium (Gentaur, cat. no. SD7002(S518)) and LB plates (BD,
cat. no. 244510) (ampicillin 100 μg ml−1 for the pQE30 vector or kanamycin 30 μg
ml−1 for the pET28-derived constructs)
• Isopropyl-β-D-thiogalactopyranoside (Chem-impex international, cat. no. 00194)
• Nickel-nitrilotriacetic acid (Ni-NTA)-agarose resin (Qiagen, cat. no. 1018240)
• Lysozyme (Sigma, cat. no. L6876)
• DNAse I (Roche, cat no. 10 104 159 001)
• Imidazole (Alfa Aesar, cat. no. A10221)
• Common reagents for SDS-PAGE analysis
• Brilliant blue R (Sigma-Aldrich, cat. no. B7920)
• Methanol, MeOH (EMD, cat. no. MX0488-1)
• Acetic acid, AcOH (VWR, cat. no. BDH3094)
• Hydrochloric acid, HCl (EMD, cat. no. HX0603-4) ! Caution
• Ethanol (Pharmco-AAPER, cat. no. 111000190)
• BCA-protein reagent assay kit (Pierce cat. no. 23227)
EQUIPMENT
• Water bath at 42°C
• Bacterial shaker
• Floor centrifuge capable of spinning 1 L bacterial cultures at 6,000 g and spinning
50-ml tubes at 20,000 g
• Motorized mechanical pipette
• French Press for lysis of bacterial cells
• Poly-prep chromatography column (Bio-Rad)
• FPLC (Äkta system or similar; GE Healthcare)
• HiLoad 16/60 Superdex 75 prep grade size exclusion chromatography column
• Amicon ultra concentrators 10 kDa NMWL (Millipore)
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• 50 mL polypropylene conical tubes (Corning or similar)
REAGENT SETUP
• LB media. Autoclave. Store at 4°C. Add the desired antibiotic just before using the
media.
• LB media agar plates. Prepare according to instructions. Autoclave. Let the media
cool-down and add the desired antibiotic. Pour into plates. Store at 4°C.
• Kanamycin, 30 mg mL−1 in water and filter sterilize. CRITICAL: store at −20 °C
(1,000× stock).
• Ampicillin, sodium salt 100 mg mL−1 in water and filter sterilize. CRITICAL:
store at −20 °C (1,000× stock).
• Isopropyl-β-D-thiogalactopyranoside, 0.5 M in water. CRITICAL: store at −20
°C (1,000× stock).
• 1 M Imidazole in nickel-binding buffer, adjusted with HCl to pH 7.8. Dilute the
imidazole stock solution in nickel-binding buffer to make the lysis, wash, and
elution buffer as indicated. Store at 4 °C.
• Lysozyme. CRITICAL: Store powder at −20 °C and dissolve at 10 mg mL−1 in
water just before use (1,000× stock).
• DNAse. CRITICAL: Store powder at 4 °C and dissolve at 10 mg mL−1 in water
just before use (1,000× stock).
• Nickel-binding buffer: 50 mM Tris·Cl, pH 7.5, 150 mM NaCl. Store at 4 °C.
• Lysis Buffer: 50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 10 mM
imidazole, 10% glycerol, 1 mg mL−1 DNase, 1 mg mL−1 lysozyme. Store at 4°C.
• Wash Buffer: 50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 10 mM
imidazole, 10% glycerol. Store at 4°C.
• Elution Buffer: 50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 500 mM imidazole, 10%
glycerol. Store at 4 °C.
• Coomassie blue staining: Dissolve 1.25 g Brilliant Blue R in a mixture of
methanol (200 mL), water (250 mL) and acetic acid (50 mL). Store in a dark
container at RT.
• Destaining solution: Mix water, ethanol and acetic acid in a ratio of 6:3:1. Store at
RT.
PROCEDURE
(A) Transform plasmid, amplify bacteria, and harvest bacteria TIMING 3 d
1. Transform competent BL21(DE3) E.coli with pET28a S. aureus sortase A (Δ59),
pET28a Ca2+ independent S. aureus sortase A (Δ59), or pET28a S. pyogenes
sortase A onto LB-kanamycin plates or E.coli with pQE30 S. aureus sortase A
(Δ25)onto LB-ampicillin plates and incubate at 37 °C overnight.
2. Start overnight culture: inoculate an individual colony from the plate into 100 mL
LB-ampicillin or LB-kanamycin media (depending on the construct) and shake at
220 rpm at 37 °C overnight.
3. Start expression culture: dilute 10 mL of the overnight culture into 1 L LB media
with the corresponding antibiotic. Shake at 37°C until A600 is 0.4–0.6 (~3 h).
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Reserve a 100 μL sample of the culture as the preinduction control for testing
sortase expression.
4. Induce protein expression: add Isopropyl-β-D-thiogalactopyranoside to a final
concentration of 0.5 mM and shake at 25°C for 16 h.
5. Harvest bacteria: Reserve a 100 μL sample of the culture as the postinduction
control for testing sortase expression. Centrifuge the culture at 6,000 g for 15 min
at 4°C. Decant supernatant. Resuspend the pellet in 50 mL nickel-binding buffer,
transfer to a 50 mL centrifuge tube using a motorized pipette and centrifuge again.
PAUSE POINT: The pellet can be frozen at −80°C and processed when convenient.
We advise analyzing the pre- and post-induction samples by SDS-PAGE before
proceeding to the purification step.
(B) Preparation of sortases TIMING 1–2d
1. Lyse the bacteria in 25 mL ice-cold lysis buffer and transfer to the chamber of a
pre-chilled French press. Lyse the cells under a pressure of 1000 psi. Allow the
bacterial lysate to cool on ice for 2 min and repeat the process. Clarify the cell
lysate at 20,000 g for 30 min at 4 °C. Keep the supernatant on ice.
2. Pack a Poly-prep column with 1–1.5 mL (bed volume) nickel-nitrilotriacetic acid
(Ni-NTA) agarose resin and wash with 10 column volumes of wash buffer (by
gravity flow). CRITICAL STEP: Do not allow the column to run dry.
3. Load the bacterial supernatant onto the column by gravity flow.
4. Wash the column with 50 column volumes of wash buffer to remove
nonspecifically bound proteins.
5. Elute with 3 column volumes of ice-cold elution (high imidazole) buffer.
6. Analyze a sample of the eluate by SDS-PAGE.
7. The sortase preparation is best further purified by gel filtration. This affords
removal of remaining contaminants and of the imidazole contained in the elution
buffer. Pre-equilibrate a Hi-Load Superdex 75 16/60 column with 40 mL nickel-
binding buffer (no imidazole), at a rate of 1 mL min−1.
8. Inject the eluted protein sample and maintain a flow rate of 1 mL min−1. Collect 1.3
mL fractions.
9. Based on the UV spectra, identify and collect the protein-containing fractions and
analyze by SDS-PAGE. Pool the fractions that contain pure sortase and concentrate
to 25 mg mL−1 using an Amicon ultra concentrator. The protein concentration is
determined by BCA assay. An aliquot of the protein is analyzed by SDS-PAGE to
check for purity.
10. Add 10% glycerol to the preparation and aliquot the enzyme. Snap-freeze and store
at −80°C, where it is stable for a long time (months). Once thawed, sortase A can
be stored at 4 °C for 1 month with no noticable loss of activity.
Note: We often detect the presence of contaminants in the preparation of the S.
pyogenes sortase A. These contaminants do not affect the activity of the enzyme,
but the enzyme preparation can be further purified by anion-exchange
chromatography (Mono Q) using a linear gradient 0–40% NaCl over 75 mL in a
Mono Q column (GE Healthcare) at a flow rate of 0.5 mL min−1. Under these
conditions, the enzyme elutes around 15–20% NaCl. Mono Q Buffer A: 50 mM
Tris·Cl, pH 8.0. Mono Q Buffer B: 50 mM Tris·Cl, pH 8.0, 1 M NaCl.
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PEPTIDE SYNTHESIS
We here describe the manual synthesis of several peptides that can be used in reactions
mediated by sortase A from S. aureus, and therefore contain glycine residues at the N-
terminus. For reactions using sortase A from S. pyogenes an alanine based peptide is used as
a nucleophile. Their synthesis follows the same protocol except for the use of Fmoc-Ala-OH
in place of Fmoc-Gly-OH. Perform two or three repeated couplings of Fmoc-Ala-OH to
obtain the di and tri-alanine sequence, respectively. Also, Fmoc-Lys(biotin)-OH, Fmoc-
Lys(5-TAMRA)-OH, and other conjugates can be purchased as premade building blocks.
These building blocks are more expensive, but reduce the time required for synthesis and
ease purification of the desired final product.
MATERIALS
REAGENTS
• N,N-Dimethylformamide (DMF; Applied Biosystems, cat. no. GEN002007) !
Caution Flammable/toxic
• Acetonitrile (JT Baker Analytical, cat. no. 9017-03) ! Caution Flammable/toxic
• N-methyl-2-pyrrolidone (NMP; Sigma Aldrich, cat. no. 328634-2L) ! Caution
Flammable/irritant/toxic
• Diisopropylethylamine (DIPEA; Fisher BioReagent, cat. no. BP592500) ! Caution
Highly flammable/corrosive
• Dichloromethane (DCM; VWR, cat. no. JT9305-3) ! Caution Carcinogen
• Dimethylsulfoxide (DMSO; EMD Chemicals Inc, cat. no. MX1458-6) ! Caution
Irritant/flammable
• Piperidine (Sigma Aldrich, cat. no. 104094) ! Caution Flammable/corrosive
• Pyridine (Sigma Aldrich, cat. no. 360570) ! Caution Highly flammable/toxic
• Diethyl ether (EMD Chemicals Inc, cat. no. EX0185-8)! Caution Highly
flammable
• Trifluoroacetic acid (TFA; Sigma Aldrich, cat. no. T6508) ! Caution Strongly
corrosive/toxic
• Triisopropylsilane (TIS; Sigma Aldrich, cat. no. 233781) ! Caution Flammable
• Ethanedithiol (Sigma Aldrich, cat. no. w348406) ! Caution Flammable and toxic
• 5(6)-carboxy-tetramethylrhodamine (TAMRA; Novabiochem, cat. no, 815030)
• Biotin (Sigma Aldrich, cat. no. B4501)
• Fmoc-Lysine(Mtt)-OH (EMD biosciences, cat. no. 04-12-1137)
• Fmoc-Cys(Trt)-OH (Novabiochem, cat. no. 852008)
• Fmoc-Gly3-OH (Chem-Impex international, cat. no. 08072)
• Fmoc-Gly-OH (Novabiochem, cat. no. 852001)
• Fmoc-Ala-OH (Novabiochem, cat. no. 852003)
• Fmoc-Lys(biotin)-OH (Novabiochem, cat. no. 852097)
• Fmoc-Lys(5-TAMRA)-OH (AAT Bioquest, cat. no. 5045)
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• 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
(HBTU; Novabiochem, cat. no. 851006)! Caution Irritant/harmful
• benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP;
Novabiochem, cat. no. 851009) ! Caution Irritant/harmful
• Ninhydrin (Eastman, cat. no. 2495) ! Caution Harmful
• Potassium cyanide (Sigma-Aldrich, cat. no. 31252) ! Caution Highly toxic
• Phenol (J.T. Baker, cat. no.2858-04) ! Caution Toxic/corrosive
• Ethanol (Pharmco-AAPER, cat. no. 111000190)
• Rink amide resin SS, 100–200 mesh, 1% DVB (Advanced Chemtech, cat. no.
SA5030)
• tert-Butanol (Aldrich, cat. no. 36,053-8)
EQUIPMENT
• 3 mL syringe and filter frit (New England Peptide, AC0-003)
• Screw cap glass peptide column with a frit filter bottom
• Wrist Action shaker (St. John Associate Inc.)
• Swing bucket centrifuge (Beckman)
• HPLC system (Agilent 1100 series)
• Reverse phase protein and peptide C18 column (Vydac, cat. no. 218TP1010)
• Liquid Chromatography/Mass Spectrometry (LC/MS)
• Nuclear Magnetic Resonance (NMR) spectrometer
• Vacuum line
• Lyophilizer
• Microfuge tubes
• Test tube racks
• Glass pipettes and Pasteur pipets
• Syringes
• Graduated cylinders
• Pipet bulbs
• Heating block
• Rotary evaporator (Buchi)
• 50 mL polypropylene conical tubes (Corning or equivalent)
REAGENT SETUP
• Kaiser test solution A dissolve 500 mg of ninhydrin in 10 mL ethanol.
• Kaiser test solution B dissolve 80 g of phenol in 20 mL of ethanol.
• Kaiser test solution C dissolve 1.3 mg potassium cyanide (20 μmol) in 20 mL of
water. Add 2 mL of the potassium cyanide solution to 100 mL of pyridine.
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• 20% piperidine in NMP mix 20 mL piperidine and 80 mL NMP.
Kaiser Test TIMING 5 min: Monitor peptide couplings by performing a Kaiser test 40.
1. Mix 2 μL of solution A, 2 μL of solution B and 4 μL of solution C in a
microcentrifuge tube.
2. Add 5–10 beads of the dried resin (obtained after the final wash step after the
coupling reaction) to the mixture.
3. Heat the tube to 95°C for 3 min. A dark blue color indicates incomplete coupling.
Note: This test works on primary amines and does not work for testing the
attachment of an amino acid to a Pro residue. Alternative methods such as the
acetaldehyde/p-chloroanil test or microcleavage can be used to monitor these
reactions 41,42.
Microcleavage Test TIMING 45 min
1. Prepare a 30 μL solution of 95% TFA and 5% H2O.
2. Add 5–10 beads to the solution and cleave for 20 min at room temperature.
3. Take 5 μL of the supernatant and dilute in 30 μL of H2O and analyze by mass
spectrometry.
A) GGGK-Biotin and GGGK-TAMRA peptides
1 Add 100 μmol of Rink amide resin (167 mg) into a capped glass column with a
fritted glass bottom, solvate the resin in DCM (7 mL) by shaking for 15 min in a
wrist-action shaker at room temperature and remove the DCM by vacuum
filtration.
2 Add 20% piperidine solution in NMP (7 mL) and shake for 15 min at room
temperature to remove the resin’s Fmoc protecting groups.
3 Remove the piperidine solution by vacuum filtration and wash the resin three
times with NMP (7ml), three times with DCM (7ml) and an additional time with
NMP (7ml).
4 Dissolve Fmoc-Lys(Mtt)-OH (188 mg, 300 μmol), HBTU (114 mg, 300 μmol),
and DIPEA (104 μL, 600 μmol) in NMP (7 mL) and add to the resin. Shake the
suspension for 2 h at room temperature.
5 Remove the reaction solution by vacuum filtration and wash the resin three
times with NMP (7ml) and three times with DCM (7ml). Confirm the coupling
reaction by performing a Kaiser test.
Note: If the reaction is incomplete, repeat steps 4–5 with half the amount of
reagents used for a standard coupling and shake for 1 h at room temperature.
PAUSE POINT: Dry the resin under vacuum and store at 4 °C. CRITICAL
STEP: Only store protected peptides.
6 Selectively remove the 4-methyl trityl (Mtt) protecting group with a solution of
97% DCM, 2% TIS and 1% TFA. Shake the peptide resin with the cleavage
solution (5 mL) for 30 min. Remove the solution by vacuum filtration; add an
additional 5 mL of cleavage solution and shake for 30 min to ensure complete
removal of the Mtt. The side chain deprotected peptide remains attached to the
resin.
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Note: The cleaved Mtt produces an orange color. Eventually the color will fade
from reaction with the TIS. If the color remains after the second 30 min reaction,
perform a third 30 min deprotection.
7 Wash the resin three times with NMP (7ml), three times with DCM (7ml), and
one additional brief wash with NMP (7ml) containing DIPEA (500 μmol, 5
equiv).
Note: This final wash step neutralizes the resin and improves the coupling
efficiency in the next step. This wash step should be brief. Prolonged exposure
to alkaline conditions may result in partial removal of the Fmoc-protecting
group.
8 To synthesize the biotin-containing probe, make a solution of biotin (74 mg,
300 μmol), HBTU (114 mg, 300 μmol) and DIPEA (104 μL, 600 μmol) in NMP
(7 mL). Add the solution to the resin and shake for 2 h at room temperature. The
reaction product consists of the G3K-biotin peptide.
To synthesize the TAMRA-containing probe, prepare a solution of 5(6)-
TAMRA (52 mg, 120 μmol), PyBOP (63 mg, 120 μmol), and DIPEA (42 μL,
240μmol) in NMP (7 mL). Add the solution to the resin and shake overnight at
room temperature. To prevent photobleaching, avoid exposure to light where
possible and wrap the column in aluminum foil.
9 Repeat step 5 to monitor biotin/TAMRA coupling.
10 Repeat steps 2–5, except use Fmoc-Gly3-OH (123 mg, 300 μmol) instead of the
Lys residue.
Note: Three repeated couplings of Fmoc-Gly-OH can be used instead of Fmoc-
Gly3-OH.
11 Remove the terminal Fmoc group as indicated in step 2–3.
12 Wash the residue an additional two times with DCM. Then suspend the resin in
a solution consisting of 95% TFA, 2.5% H2O, and 2.5% TIS (5 mL) for 2 h at
room temperature.
13 Elute the cleavage solution into 90 mL of ice cold (-20 °C) diethyl ether and
rinse the resin with an additional 3 mL of the cleavage solution into the ether.
14 Store the ether solution at −20 °C for 20 min to precipitate the peptide.
Centrifuge the suspension at 3,500 rpm for 15 min at 4 °C, decant the
supernatant and gently evaporate the remaining ether under reduced pressure.
PAUSE POINT. The crude peptide can be stored as a solid at −20 °C.
15 Dissolve the dried peptide in water (2 mL) and centrifuge at 14,000 rpm for 10
min.
Note: Up to 50% of tert-butanol may be added to peptides that do not readily
dissolve in pure water.
16 Purify the centrifuged supernatant by reverse-phase HPLC on a C18 column
using a 10–90% water-acetonitrile gradient with 0.1% TFA.
17 Analyze the fractions for the presence of the desired product by LC/MS and
lyophilize the desired fractions to dryness.
Critical step. Verify the identity and purity by LC/MS analysis (linear gradient
5–45% acetonitrile in 10 min) and NMR spectroscopy. If LC/MS shows the
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crude peptide is of sufficient purity, this HPLC purification may be omitted and
the peptide may be used directly in sortase reactions.
Note: TAMRA-containing probes consist of mixture of regio-isomers, which are
easily separated by reverse phase HPLC.
PAUSE POINT. The lyophilized peptide can be stored at −20 °C indefinitely.
B) GGGK NHS Ester Probes: In-solution coupling of NHS esters to (partially) protected
peptides provides a route to couple base/acid labile and/or more costly dyes (such as Alexa
fluor 647) or other suitable precursors to a GGG-containing peptide.
1 Follow steps 2–5 of the GGGK-biotin/TAMRA probe synthesis, but using
Fmoc-Lys(Boc)-OH (141 mg, 300 μmol) instead of the Mtt protected Lys.
2 Follow steps 2–5 from the GGGK-biotin/TAMRA, substituting Fmoc-Gly3-OH
(123 mg, 300 μmol) for the Lys residue.
3 Cleave and precipitate the peptide from the resin with the Fmoc group still on
the terminal Gly as described in steps 12–15 for the GGGK-biotin/TAMRA
probes.
Critical step. It is crucial to leave the Fmoc-protecting group on the peptide, as
it prevents unwanted side reactions during the NHS ester coupling.
Critical step. Hydrophobic peptides may precipitate poorly. Dry the supernatant
of the ether precipitation by rotary evaporation to increase the yield.
PAUSE POINT. Store the crude peptide at −20 °C.
4 Purify the peptide by reverse phase HPLC as indicated in steps 15–17 for the
GGGK-biotin/TAMRA probes.
Note: If LC/MS shows the crude peptide is of sufficient purity, this HPLC
purification may be omitted.
Note: tert-Butanol may be added to peptides that do not dissolve in pure H2O
prior to HPLC purification.
5 Dissolve the peptide in DMSO.
6 Add three to five equivalents of the Fmoc-GGGK peptide in DMSO to the NHS
ester and add 5 equivalents of DIPEA.
7 Incubate the reaction for 16 h at room temperature.
Note: to prevent photobleaching or photoconversions, exclude the peptide from
light by covering its containers in aluminum foil.
Critical step. It is important to leave the reaction for 16 h. Although the
coupling of the NHS ester may be faster, the added DIPEA also facilitates
(slow) removal of the Fmoc-protecting group.
8 Acidify the reaction mixture with 0.1% aqueous TFA and purify the peptide by
reverse phase HPLC as described in steps 15–17 for the GGGK probes
synthesis.
C) GGGC Maleimide-containing Probes: An alternative for the installation of chemical
groups of interest onto a peptide is to use a cysteine-maleimide reaction. The procedure is
similar to that of the GGGK NHS ester peptide, except the lysine is replaced by a cysteine
and a maleimide-derived dye/probe is substituted for the NHS ester.
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Note: Under the appropriate conditions, the maleimide will react with the cysteine
exclusively and therefore fully deprotected peptides can be used.
Note: Prolonged storage of the probe in aqueous solution can result in hydrolysis of the
maleimide. The resulting ring-opened product is still an excellent probe for the sortase
reaction, but may cause difficulty during ion-exchange purification of the sortagged
proteins. It is therefore crucial that probes containing maleimide-coupled functional groups
are stored as lyophilized powders.
1 Repeat steps 1–5 as described for the GGGK probes with Fmoc-Cys(Trt)-OH to
load the resin.
2 Repeat steps 2–5 as described for the GGGK probes using Fmoc-Gly-Gly-Gly-
OH.
3 Repeat steps 2–3 from the GGGK probes to remove the N-terminal Fmoc-
protecting group.
4 Cleave the peptide from the resin by incubating the resin twice with 1 mL of a
cleavage cocktail containing 93% trifluoracetic acid, 2.5% triisopropylsilane,
2% ethanedithiol and 2.5% water for 2 h.
Critical step. Addition of ethanedithiol prevents formation of disulfide bridges.
5 Precipitate and collect the peptide as described in steps 13–14 for the GGGK
probes.
6 Remove the supernatant and dissolve the pellet in 2 mL of methanol.
7 Precipitate and collect the peptide as described in steps 13–15 for the GGGK
probes. Critical step. Removal of residual of ethanedithiol is critical since even
trace amounts can interfere in the maleimide-thiol reaction.
8 Analyze, purify (if needed) and lyophilize the crude H2N-GGGC-CONH2 as
described in step 17 for GGGK probes.
PAUSE POINT. Store the lyophilized peptide at −20 °C until needed.
9 Dissolve the peptide (2 equiv.) in PBS (0.25 mL) and add maleimide (1 equiv.)
in DMF or DMSO (0.25 mL).
10 Incubate overnight at room temperature and subsequently quench the reaction
with 0.1% aqueous TFA (2 mL).
11 Purify, analyze and lyophilize the product as described in steps 16–17 for
GGGK probes.
Critical step. Verify the identity and purity by LC/MS analysis (linear gradient
5–45% acetonitrile in 10 min) and NMR spectroscopy.
PAUSE POINT. Store the purified product at −20 °C.
C-TERMINAL SORTAGGING REACTIONS
MATERIALS
REAGENTS
• Purified target protein in buffer (no phosphate-based buffer if a Ca2+-dependent
sortase A is used)
• Purified sortase A in buffer (no phosphate-based buffer if a Ca2+-dependent sortase
A is used)
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• Oligoglycine peptide (if using S. aureus sortase A) or dialanine or trialanine
peptide (if using S. pyogenes sortase A) stock solution: 10mM in DMSO or water
(10x stock). If an oligoglycine protein is used as the nucleophile, then dissolve it in
buffer (no phosphate-based buffer if a Ca2+-dependent sortase A is used)
• Nickel-nitrilotriacetic acid (Ni-NTA)-agarose resin (Qiagen, cat. no. 1018240)
• Imidazole (Alfa Aesar, cat. no. A10221)
• 4x loading LDS-buffer (Invitrogen NP0008)
• Common reagents for SDS-PAGE and for Coomassie staining (see “Expression
and production of sortases” section)
EQUIPMENT
• Micropipettes (5–1000 μL)
• 1.5 mL centrifuge tubes
• Centrifuge for 1.5 mL centrifuge tubes
• 37 °C water bath
• End-over-end shaker
• Heating block
• Desalting PD-10 columns (GE Healthcare, cat. no. 17-0851-01)
REAGENT SETUP
• Sortase buffer: 500 mM Tris-HCl pH 7.5, 1.5 M NaCl, 100 mM CaCl2 (not
required if using a Ca2+-independent sortase) (10x stock).
• Nickel-binding buffer: 50 mM Tris-HCl pH 7.5, 0.5 M NaCl, 10 mM imidazole.
Store at 4°C.
• 1 M Imidazole in nickel-binding buffer, adjusted with HCl to pH 7.8. Dilute the
imidazole stock solution in nickel-binding buffer to make the lysis, wash, and
elution buffer as indicated. Store at 4°C.
PROCEDURE
A) Setting up the reaction conditions
1. Mix a solution containing 10–50 μM target protein, 20–150 μM sortase, 1–2 mM
oligoglycine probe in 1x sortase buffer (final concentrations). The controls to be
included are: target protein only, sortase only, oligoglycine probe only, target
protein and sortase, target protein and oligoglycine probe, sortase and oligoglycine
probe.
2. Incubate the reactions at RT or at 37°C. Take 1 μL aliquots after 2, 4, 6, 8 and 16 h.
Add 1x LDS-gel loading buffer to the aliquots to stop the reaction and boil 2 min.
PAUSE POINT: The aliquots can be frozen at −20 °C until further analysis.
3. Analyze the aliquots by SDS-PAGE followed by Coomassie staining.
Anticipated result: A successful sortase reaction often results in the formation of the acyl-
enzyme intermediate if the oligoglycine probe is omitted. Small quantities of hydrolysis
product (loss of (His)6 or epitope tag may occur upon cleavage of the sortase motif in the
absence of added nucleophile. The acyl-enzyme intermediate usually survives reducing
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SDS-PAGE in detectable amounts. A full sortase reaction often yields a reaction product of
mobility distinct from that of the input substrate and the hydrolysis product. The ability to
distinguish the various intermediates critically depends on the molecular weight of the
anticipated products and the gel systems used to analyze them.
(B) Purification: Overview: Because the protein substrate is constructed with a His6 handle
downstream of the LPXTG/A motif (see section “Engineering substrates for sortagging”),
the protein substrate molecules that were not labeled will retain the His6 tag upon reaction.
The sortases are themselves tagged with His6. Thus, a convenient strategy to separate the
labeled product from sortase and unreacted substrate is the use of affinity-chromatography
(Ni-NTA beads), followed by HLPC or by a desalting column to remove the unreacted
peptide nucleophile. Critical step. Check compatibility of the incorporated functionality
with Ni-NTA purification. We have noted that some functional groups, including
acylhydrazones, bind to the resin.
1. Pipette 500 μL of the Ni-NTA resin (50% slurry) into a microcentrifuge tube.
Centrifuge at 280 g, 5 min, 4 °C. Discard the supernatant. Wash the resin three
times using 1 mL of nickel-binding buffer.
CAUTION: Do not let the beads dry.
2. Dilute the sortase reaction with nickel-binding buffer to a final volume of 500 μL
(We recommend taking an aliquot of 5 μL from the diluted reaction to later
determine the efficiency of purification). Add to the Ni-NTA resin. Agitate on an
end-over-end shaker for 30 min, 4°C.
3. Centrifuge at 280 g, 5 min, 4°C. Keep the supernatant.
4. Add 500 μL of nickel-binding buffer to the resin, agitate on an end-over-end shaker
for 10 min, 4°C.
5. Centrifuge at 280 g, 5 min, 4°C. Keep the supernatant.
6. Combine the supernatants obtained in steps 3 and 5. Take an aliquot and analyze
together with the aliquot taken in step 2 by SDS-PAGE.
7. If further purification is required to remove free peptide nucleophile, we
recommend using a desalting column equilibrated in a buffer of choice, depending
on the use of and compatibility with the labeled protein. Purification by gel
filtration is an alternative. We use the same protocol described in the section
“Expression and production of sortases”.
Anticipated results: The exact reaction conditions for protein labeling need to be determined
empirically for each protein substrate. The range provided has yielded acceptable results in
the majority of the cases. To achieve maximal levels of labeling, it is helpful to titrate the
sortase, substrate, and probe concentrations relative to one another, to vary the time of
labeling, and the temperature of reaction.
Troubleshooting
Problem Possible cause Solution
No sortase expression Wrong antibiotic selection Confirm you used the right antibiotic
No induction Make sure you are using BL21(DE3)
E.coli bacteria
Prepare a fresh solution of IPTG
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Problem Possible cause Solution
No protein labeling No acyl-intermediate is being
formed
(see below)
Not enough nucleophile added to
the reaction
Reaction conditions have to be determined ad-
hoc. Increase the amount of nucleophile to 10
mM and/or decrease the amount of substrate
pH of the reaction buffer not
compatible with sortase activity
Ensure that the pH of the reaction buffer is
neutral. Check the pH of the stock solutions.
Probe solutions have the tendency to have a low
pH due to residual traces of TFA. Multiple
rounds of lyophilization and/or neutralization
with buffer or aq. NaHCO3 solves this issue
Proteolysis of sortase Verify the integrity of sortase upon reaction by
coomassie staining or anti-His blot. The amount
of sortase before and after reaction should be
equal. If not, consider the presence of a
contaminating protease, which most probably co-
purified with the protein of interest. We
recommend further purification of the protein
substrate.
No acyl-intermediate is
observed in the substrate-
sortase control
The substrate is not correctly
engineered
Confirm that the LPXTG/A motif is in frame and
that no stop codons exist upstream of this
sequence
Ensure that one or a few amino acids are present
downstream of the Gly/Ala residues (Gly/Ala in
LPXTG/A must be in amide linkage)
The LPXTG/A motif is not well
exposed or it is designed in a
conformationally constrained
region of the protein
Extend the C-terminus of the protein introducing
a linker (Gly4Ser)2 immediately upstream of the
sortase motif
Sortase is inactive Test the preparation of sortase using
GFP.LPETG/A.His6 as the substrate
Not enough sortase added to the
reaction
Sortase concentration has to be titrated for each
substrate to be labeled. Increase the substrate
concentration and/or decrease the amount of
protein to be labeled
Detection of a circular form
of the protein when
attempting labeling the C-
terminus. The circular
versions of such sortase
substrates often show more
rapid migration on SDS-
PAGE than their linear
counterparts.
The N- and C-termini of the
protein are in close proximity and
the N-terminal amino acid of the
protein (Gly or Ala) acts as a
nucleophile
Confirm that the first amino acid in the protein
of interest is not a Gly or Ala. If it is, mutate it to
Ser for example. If the first amino acid has to be
a glycine or an alanine, design a thrombin
cleavage site (LVPR) immediately upstream the
first amino acid and proceed to digestion with
thrombin upon sortase labeling, to expose the
Gly or Ala residues. It is possible that a Lys
residue close to the N-terminus can serve as the
incoming nucleophile for circularization.
Consider this possibility if replacement of N-
terminal Gly or Ala fails to suppress
circularization.
Detection of a white fluffy
precipitate during the sortase-
labeling reaction
Ca2+ precipitate Do not use phosphate buffers
Protein is precipitating during
the labeling reaction
High concentration of protein,
specially when attempting
protein-protein fusions
Optimize reaction temperature and incubation
time so less protein may be used to achieve the
same reaction yield without precipitation
The protein of interest
precipitates at high temperatures
Perform the labeling reaction at RT and extend
the reaction time
No labeling when attempting
modification at an internal
site even when the site is
nicked by a protease
The region is not flexible or
accessible.
Extend the sequence of the protein by a few
amino acids. The number of amino acids
required must be determined empirically.
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Figure 1.
Schematic representation of how proteins are anchored to the cell wall via sortase in Gram-
positive bacteria. See text for details. Adapted from 17.
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Figure 2. C-terminal labeling of proteins
A protein modified at its C-terminus with the LPXTG sortase recognition motif followed by
a handle (usually His6) is incubated with S. aureus Sortase A. Sortase cleaves the Thr-Gly
bond and via its active site Cys residue forms an acyl intermediate with Thr in the protein.
Addition of a peptide probe comprising of a series of N-terminal glycine residues and a
functional moiety of choice resolves the intermediate, thus regenerating the active site
cysteine on sortase and ligating the peptide probe to the C-terminus of the protein.
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Figure 3. Labeling of an internal loop of a protein
A protein comprising a loop formed by the establishment of a disulfide bond is modified to
contain the sortase recognition motif (LPXTG) followed by a specific protease cleavage site.
To increase flexibility of the LPXTG-containing region, the loop is nicked with the protease
of choice and the sortase-mediated reaction follows as described for C-terminal labeling.
Note however that as long as the region containing the LPXTG motif is flexible and
accessible, a proteolytic event might not even be required. The presence of a disulfide bridge
is also not critical for the reaction. While such a bond is convenient to ensure that the protein
will not disintegrate upon labeling, at times the topology and conformation of the protein of
interest naturally ensures integrity.
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